PPIs therapy has a negative impact on the clinical outcomes of advanced SCLC patients treated with PD-L1 inhibitors

BACKGROUND: Programmed death-ligand 1 (PD-L1) inhibitors has emerged as a first-line therapeutic strategy for advanced small cell lung cancer (SCLC), which can stimulate T-cell activation, thereby preventing tumor avoidance of immunologic surveillance, whereas, proton pump inhibitors (PPIs) can play...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Sisi, Tian, Jing, Wang, Xinwei, Liu, Chengxin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638834/
https://www.ncbi.nlm.nih.gov/pubmed/37951887
http://dx.doi.org/10.1186/s12890-023-02754-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10638834/
https://www.ncbi.nlm.nih.gov/pubmed/37951887
http://dx.doi.org/10.1186/s12890-023-02754-4

Ejemplares similares